We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
- Authors
Yan, P.; Butt, A. A.; Shaikh, O. S.; Abou‐Samra, A.‐B.
- Abstract
Summary: Background: Higher risk of hepatitis B reactivation (HBV‐r) has been reported in patients with hepatitis C treated with newer directly acting antiviral agents (DAAs). Aim: To determine the proportion of persons who develop HBV‐r and its clinical consequences among DAA treated vs pegylated interferon/ribavirin (PEG/RBV) treated persons. Methods: We calculated the proportion of persons who developed HBV viral reactivation (HBV‐r; new detectable HBV DNA or increase of >1 log10); serum alanine aminotransferase flare (>5 times baseline); all‐cause mortality and hepatic decompensation in persons treated with a newer DAA regimen or PEG/RBV. Kaplan‐Meier curves were used to demonstrate survival and hepatic decompensation by treatment group and HBV‐r. Results: In 34 632 persons treated with DAA and 23 475 treated with PEG/RBV, HBV‐r rate per 1000 person‐years was 30.04 (10.41, 49.67) and 25.42 (95% CI 17.23, 33.62) respectively (<italic>P</italic> = .8). When stratified by SVR or by baseline HBsAg status, HBV‐r was not different between groups. Kaplan‐Meier survival curves comparing each regimen stratified by presence or absence of HBV‐r did not demonstrate a significant difference in incidence of hepatic decompensation over time. For overall survival, there was no difference between PEG/RBV treated persons with or without HBV‐r. For DAA treated persons, those with HBV‐r had a shortened survival, though the numbers at risk were small. Conclusions: HBV‐r is relatively uncommon after DAA therapy and not higher than among those treated with a PEG/RBV regimen. The small numbers of persons treated with a DAA regimen who do develop HBV‐r have a shortened survival compared to those without HBV‐r.
- Subjects
HEPATITIS B; HEPATITIS C treatment; ANTIVIRAL agents; RIBAVIRIN; KAPLAN-Meier estimator; DISEASE risk factors
- Publication
Alimentary Pharmacology & Therapeutics, 2018, Vol 47, Issue 3, p412
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.14426